dnaJP1

Prof Salvatore Albani · Phase 2 active Small molecule Quality 0/100

At a glance

Generic name	dnaJP1
Sponsor	Prof Salvatore Albani
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

An Artificial Intelligence-powered Approach to Precision Immunotherapy of Human Arthritis (PHASE2)
dnaJ Peptide for Relieving Rheumatoid Arthritis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

dnaJP1 CI brief — competitive landscape report
dnaJP1 updates RSS · CI watch RSS
Prof Salvatore Albani portfolio CI